咪唑并[1,2-a]吡啶-6-碳酰肼 | 886361-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-a]吡啶-6-碳酰肼
• 英文名称: imidazo[1,2-a]pyridine-6-carbohydrazide
• 英文别名: imidazol[1,2]pyridine-6-carboxylic hydrazide；imidazo[1,2-a]pyridine-6-carboxylic acid hydrazide
• CAS: 886361-97-3
• 化学式: C₈H₈N₄O
• mdl: MFCD07021499
• 分子量: 176.178
• InChiKey: ZMQNWDRVASCREF-UHFFFAOYSA-N

物化性质

• 熔点：
  219-221°
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  咪唑并[1,2-a]吡啶-6-甲酸甲酯	methyl imidazo[1,2-a]pyridine-6-carboxylate	136117-69-6	C9H8N2O2	176.175

反应信息

• 作为反应物：
  描述：

  二硫化碳 、 咪唑并[1,2-a]吡啶-6-碳酰肼 在 三乙胺 作用下， 以 乙醇 为溶剂， 以80%的产率得到5-imidazo[1,2-a]pyridin-6-yl-1,3,4-oxadiazole-2-thiol
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β

  摘要：

  Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3beta inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3beta.

  DOI：

  10.1016/j.bmc.2009.01.019
• 作为产物：
  描述：

  咪唑并[1,2-a]吡啶-6-甲酸甲酯 在 一水合肼 作用下， 以79%的产率得到咪唑并[1,2-a]吡啶-6-碳酰肼
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β

  摘要：

  Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3beta inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3beta.

  DOI：

  10.1016/j.bmc.2009.01.019

文献信息

• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。
• New phenylhydrazone derivatives and their use as pharmaceuticals
  申请人：Arteria

  公开号：EP2338879A1

  公开（公告）日：2011-06-29

  A compound of general formula (I) : a process for preparing the same, a pharmaceutical composition comprising said compound comprising such compound and its use for treating or preventing diseases related to the metabolic syndrome such as hepatic and cardiovascular diseases.

  通用公式(I)的化合物：制备该化合物的方法，包括该化合物的药物组合物，以及用于治疗或预防与代谢综合征相关的疾病，如肝脏和心血管疾病的用途。
• [EN] NEW PHENYLHYDRAZONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] NOUVEAUX DÉRIVÉS DE PHÉNYLHYDRAZONE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：ARTERIA

  公开号：WO2011073165A1

  公开（公告）日：2011-06-23

  A compound of general formula (I) a process for preparing the same, a pharmaceutical composition comprising said compound comprising such compound and its use for treating or preventing diseases related to the metabolic syndrome such as hepatic and cardiovascular diseases.

  一种具有一般式(I)的化合物，其制备方法，包含该化合物的制药组合物，以及其用于治疗或预防代谢综合征相关疾病，如肝脏和心血管疾病的用途。
• GSK-3β inhibitor
  申请人：Itoh Fumio

  公开号：US08492378B2

  公开（公告）日：2013-07-23

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁唑烷化合物或其盐或前药的GSK-3β抑制剂，该抑制剂可用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种包含式（I）所表示的化合物的GSK-3β抑制剂：其中每个符号如规范中所定义，或其盐或前药。
• US8492378B2
  申请人：——

  公开号：US8492378B2

  公开（公告）日：2013-07-23